Discussion
A systematic review and meta-analysis of individual patient data including 10 trials with 3,229 subjects reported information on the adverse effects of invasive HFOV as well as the lack of superiority over conventional mechanical ventilation [
26]. In searching for NIV support modes able to reduce mortality and BPD risk in preterm infants with RDS, nasal HFOV emerged as a potentially effective strategy. With the increased availability of hybrid ventilators, able to deliver both invasive (including HFOV support) and NIV, and with more and more studies in the literature, nHFOV has emerged in recent years as an important initial and rescue NIV mode for preterm infants with RDS.
Nasal HFOV combines beneficial effects of CPAP and HFOV: non-invasive nasal interface, increased functional residual capacity, improved oxygenation offered by CPAP support, and reduced volu-trauma and barotrauma (due to small tidal volumes), optimization of lung volume (determined by almost constant alveolar pressure), increased stability of the distal airways, increased CO
2 removal, and reduced risk for lung injury offered by HFOV [
2,
3,
9,
27,
28]. Also, nHFOV needs no synchronization as it allows spontaneous breathing [
11,
29]. Studies have shown that nHFOV promotes the continuous opening of the glottis as supraglottic CPAP [
30,
31], facilitating the interaction between patient and machine [
9]. The continuous distending pressure delivered during NHFOV significantly reduces the shear stress of the airways and lungs, potentially reducing the BPD risk [
9]. Another important advantage of nHFOV is the possibility of using different interfaces: nasal/facial masks, short nasal prongs, RAM nasal cannula, and nasopharyngeal tubes. Oscillations in nHFOV significantly reduce the surface tension, possibly improving surfactant function [
32]. Studies in animal models showed increased production of surfactant protein B and better alveolarization [
31,
33]. Based on these effects, de Luca and Dell’ Orto [
9] speculated that oscillations applied before surfactant administration may improve surfactant function. Rehan et al. [
33], in a study on an animal model of BPD showed that nHFOV promotes coordinated expression of epithelial and mesenchymal paracrine signaling pathways of alveolar homeostasis compared to the inhibiting effect of IMV. Lack of paracrine signaling and immaturity of the alveolar type II cells are associated with lesions secondary to barotrauma, hyperoxia, and infection, which impact cellular differentiation and increase the BPD risk [
33]. Nasal HFOV was associated with reduced inflammatory markers compared to conventional ventilation [
34]. Studies with electrical impedance tomography have shown that oscillatory volumes are substantially transmitted to the lungs, including in areas non-dependent on gravity during nHFOV [
35], increased and more homogeneous aeration, increased end-expiratory lung volumes, and similar homogeneity of ventilation as compared to NCPAP [
36]. Hypothetically, nHFOV should be more efficient than other NIV modes due to all these effects, at least in some particular clinical situations. Most of the studies performed in the last years confirm the superiority of nHFOV to NCPAP and BiPAP [
10,
13,
14,
15,
16,
17,
18] and demonstrate at least the non-inferiority of nHFOV to NIPPV [
19,
20,
21,
22,
23,
24,
25] as a primary or rescue NIV support in preterm infants with RDS or after extubation from IMV.
Our study is the first performed in Romania regarding the utilization and clinical application of nHFOV. As more literature supports this novel mode of NIV support, experts worldwide are trying to more clearly establish guidelines for nHFOV regarding indications, appropriate settings, and weaning from nHFOV. More information and training are needed for Romanian neonatologists. In Romania, according to our legislation regarding the regionalization of maternal and neonatal care [
37,
38], level III neonatal units offer the highest level of neonatal care.
The response rate to our survey was similar (91.2 versus 92%) to that of Fischer et al. [
39] in 2015 from five European countries regarding the use of nHFOV. In our study, the clinical experience with nHFOV was markedly higher than in the study of Fischer et al. [
39], that reported that 30 of the 172 units answering the survey (17%) were using nHFOV (5% in Sweden to 20% in Germany) [
39]. Low nHFOV rates of 18% were also reported in Canada by Mukerji et al. [
40] in 2016, based on a survey of 28 neonatal centers. Another survey, developed in Italy in 2019 and involving 113 level III neonatal centers, has shown that nHFOV was used only in 6/113 centers (5,3%) [
41]. We have not found recent data to compare the nHFOV usage rate in our survey. Interestingly, another Romanian survey recently reported that in 2018 invasive HFOV was used in 60.6% of the level II and III Romanian NICUs (20 in 33 units responding to the survey) [
42], suggesting an increased interest and experience with HFOV and possibly nHFOV (with the increased number of hybrid ventilators) in Romania.
Our survey also included questions about NIV modes used in the level III NICUs. We have found that nasal CPAP, either with specific equipment or using a mechanical ventilator, was the most used NIV mode in the NICU (over 95.2% and 66,6%, respectively), similar to 100% CPAP use reported by Petrillo et al. [
41], Mukerji et al. [
40], and Cucerea et al. [
42]. The rate of BiPAP use was lower (47.6%) compared to the 79% rate reported by Mukerji et al. [
40] and 74.3%, reported by Petrillo et al. [
41]. We were surprised by the increased use of NIPPV in Romania (76.2%) as compared to 54% reported in Canada [
40] and 40% reported in Italy [
41]. However, the explanation may be that these surveys dated more than five years ago, and NIPPV emerged as an important rescue NIV mode in recent years [
21,
24].
The preferred interfaces used for NIV in our survey were the short nasal prongs, the facial/nasal mask (both used in 76.2% of the responding centers), and nasal cannulas (61.9%), rates comparable with those reported by Fischer et al. [
39] (73% for short nasal prongs). Nasopharyngeal tube (9,5%) and RAM cannula (23.8%) are rarely used in Romanian NICUs for delivering NIV, even rarely in the delivery room (none of the units reported use of the nasopharyngeal tubes for NIV in the delivery room while only 1 unit reported use of RAM cannula). This information contrasts the frequency of 63% use of a single nasopharyngeal tube for NIV reported by Fischer et al. [
39]. The high usage rate of masks in the delivery room in our survey (95.2) is higher than the rate reported by Gizzi et al. [
43] for centers caring for high-risk neonates (83.6%); short nasal prongs were more often used in level III units in Romania in the delivery room compared to similar units in Italy (23.8% versus 11.8%), while the nasopharyngeal tube was also rarely used in Italian centers. A recent European survey [
44] found significantly different preferences for NIV interfaces in the delivery room, but face masks were also the most used (75.9%); short binasal prongs use was reported with rates similar to our survey (20.2%), while nasopharyngeal tubes (either binasal or single) were rarely reported (less than 4%). The recent Romanian report on neonatal resuscitation and stabilization practices in the delivery room confirms that the face mask is the most frequently used interface in level III neonatal units (72.7%), followed by the short binasal prongs (27.3%) [
42].
As the new guidelines for RDS management are recommending NIV and less invasive surfactant administration in preterm infants with spontaneous breathing and clinical signs of RDS [
45], we were also curious about the frequency of use of less invasive surfactant administration (LISA) versus and intubation, surfactant administration followed by extubation on NIV support (INSURE) techniques. The survey showed a clear tendency of these approaches compared to the older data [
42] – LISA use increased from 7.1% to 66.7%, and INSURE use increased from 40.0% to 71.4%, suggesting an increased interest in reducing the risk of intubation and prolonged mechanical ventilation and good compliance with European consensus guideline recommendations.
Nasal HFOV is used quite frequently in almost half of the level III units in our survey; still, a protocol for nHFOV use is in place in only 3 of these units. According to the answers received, nHFOV is used in all categories of preterm infants and in term infants in most of the surveyed units (
Table 3). Also, Romanian neonatal units use nHFOV for all the indications reported in the literature, most commonly as a rescue NIV after CPAP failure (90.9%), similar to the results of Fischer et al. [
39] study that reported nHFOV use for CPAP failure in 90% of the units in their survey, primarily in preterm infants with birth weight <1500 g with CPAP failure. Interestingly, the reported CPAP levels considered for switching from CPAP to nHFOV are pretty low (6-7 cmH
2O reported by 7 of the 11 units using nHFOV, while the other 4 units reported 8 cmH
2O. A minimum CPAP level of 6 cmH
2O is recommended in the European guidelines for RDS management [
45]. Initial CPAP levels of 5-7 cmH
20 were reported in the 2018 survey in preterm infants with RDS in the delivery room by all the 12 level III neonatal units in Romania [
42]. Nasal HFOV support was reported as successful as a rescue mode starting in 1998 by Hoeven et al. [
8]; 77% of the patients in the study, term and preterm infants with moderate respiratory failure, avoided IMV. Another study retrospectively evaluated the nHFOV efficiency as rescue therapy after CPAP or BiPaP support and found a success rate of 69% in avoiding intubation [
46]. No difference was noted in our survey regarding the means and median (IQR) values of CPAP level before switching from CPAP to nHFOV (p = 0.931)(
Table 4).
A high percentage (81.8%) of the surveyed units reported nHFOV use in patients with hypercapnia, far more frequent compared to Fischer’s et al. survey [
39], most probably due to numerous studies that reported an improved CO
2 removal with this NIV mode compared to CPAP or NIPPV [
2,
10,
14,
47,
48,
49,
50,
51]. Eight of 11 units in our survey reported nHFOV use as a respiratory support mode in BPD. This indication is still unclear in the literature. However, as BPD may be considered a mixed model of restrictive and obstructive respiratory disease characterized by hypercapnia and hypoxemia, it may benefit from nHFOV effects [
9]. Nasal HFOV may be helpful in the evolving, exudative phase of BPD, a situation characterized by increased resistance of the airways and alveolar edema with decreased compliance as nHFOV allows the use of higher mean airway pressure, avoiding air trapping, and improving hypercarbia [
10,
52]. De Luca and Dell’Orto [
9] suggested starting settings for nHFOV in patients with evolving BPD.
The most studied indication for nHFOV support is after extubation from IMV. Nasal HFOV is used as respiratory support after extubation in 7 of the 11 units in our survey, similar to the results of another report (15 of the 30 units) [
39]. Recent studies, systematic reviews, and meta-analyses support nHFOV as an efficient NIV strategy post-extubation in preterm infants. Compared to NCPAP [
13,
20,
22,
50,
53] and BiPaP [
10], nHFOV was associated with significantly lower rates of reintubation and more effective CO
2 removal. Compared to NIPPV [
19,
20,
21,
22,
25], nHFOV significantly reduced reintubation rates, was more efficient in CO
2 removal, and decreased IMV duration. In another recent randomized controlled trial including extremely preterm infants, nHFOV and NIPPV, compared to NCAP, significantly reduced the reintubation rate, with a number needed to treat of 3 to 7, nHFOV significantly decreased moderate to severe BPD rate, with a number needed to treat of 8-9 [
23]. A significantly reduced rate of reintubation is clinically significant as reintubation is associated with an increased risk of BPD and death [
54]. Therefore, nHFOV may provide an important option in choosing the NIV support mode after extubation in preterm infants. A recent report suggests that using nHFOV after extubation significantly reduces BPD rates and length of hospitalization [
22].
Many studies in the literature support nHFOV use as primary NIV support in preterm infants with RDS, an indication also suggested by the most recent European guideline on RDS management [
45]. In our survey, 6 units (54.5%) reported using nHFOV as initial respiratory support in RDS and for alveolar recruitment, suggesting compliance with the most recent recommendations and knowledge of the results of the studies in the literature. The first RCT comparing nHFOV with NCPAP as primary support mode in preterm infants born at 28-34 weeks gestation showed significantly lower rates of mechanical ventilation with nHFOV (p <0,01) and decreased BPD and mortality rates (p > 0,5) using non-dedicated equipment for nHFOV delivery [
55]. A significantly reduced need for intubation was reported by a large study in China with nHFOV as the primary support mode in preterm infants with RDS compared to NCPAP (p = 0.016) and NIPPV (p = 0.027) [
19]. Significantly decreased rates of intubation and BPD risk were also reported by another RCT performed in preterm infants for the entire study group (N = 88) and in subgroups based on gestational age (26-29 weeks and 30-32 weeks of gestation, respectively) [
56]. With nHFOV as primary support mode in preterm infants with RDS, reduced risk of intubation was also reported in recent meta-analysis compared to NCPAP – relative risk (RR): 0.47 (95% CI 0.30-0.70), p = 0.0002 [
15], RR 0.45 (95% CI: 0.37-0.55), p < 0.01 [
18], and compared to CPAP and BiPAP – RR 0.50 (95% CI: 0.36-0.70) [
14]. Unfortunately, experts are still searching for the best candidates and the most suitable clinical indications for nHFOV to improve the outcomes of NICU patients [
10,
57,
58].
Our survey, similar to Fisher et al. [
39], found that nHFOV is delivered in the NICU with various types of ventilators specifically designed for nHFOV (e.g., Medin CNO) or hybrid mechanical ventilators (
Table 3). The choice of equipment is likely influenced by each unit’s financial resources, experience, and preference, highlighting the practical considerations in nHFOV delivery.
De Luca et al. [
9,
59] suggested the face mask as the most efficient interface for oscillation transmission and tidal volume delivery with nHFOV as oscillation attenuation is reduced compared to other interfaces. The same was demonstrated by King et al. [
60]. Our survey showed that face/nasal masks are the preferred interfaces for nHFOV delivery by 10 of the 11 units surveyed. Short nasal prongs are also used extensively, with 8 units indicating their use with nHFOV. Our results are in contrast to the survey performed by Fischer et al. [
39] that showed a preference for nasal prongs (22 of 30 NICUs) and a single nasopharyngeal tube (19 NICUs) and a low rate of face/nasal masks (8 NICUs). The Canadian survey [
40] showed similar results: preference for nasal masks and short binasal prongs with nHFOV use.
Interpretation of the answers to questions on parameters used when initiating and during nHFOV is quite difficult as dedicated ventilators and hybrid ventilators use different settings to deliver nHFOV. Also, in clinical practice, starting values of the frequency, amplitude, and mean airway pressure also depend on the clinical indication and clinical condition of the patient. This is one problem encountered by experts who tried to define recommendations for nHFOV settings with different equipment and in different situations (e.g., post-extubation, in BPD) [
2,
9,
16]. Some studies recommend setting a MAP equal to or higher with 1-2 cmH
2O compared to CPAP or PEEP when using nHFOV as a rescue mode from other NIV respiratory support [
46,
52,
61] or adjusting MAP as during the recruitment maneuvers [
13]. Initial, minimum, and maximum frequency, amplitude, and MAP reported in our survey were compared between units using dedicated equipment for nHFOV support (Medin CNO) and those using mechanical ventilators (
Table 4). We have found no difference in the frequencies used with nHFOV between the two study groups. As expected, the amplitudes used with dedicated nHFOV ventilators were significantly lower than those used with non-dedicated ventilators (p <0.017). The MAP values were also lower with special nHFOV machines, the difference being significant only for initial and minimum MAP (p = 0.004). Compared to the results of the survey published by Fischer et al. [
39] that used mostly nHFOV delivered by mechanical ventilators, our survey showed similar median frequencies (10 Hz) and oscillation amplitudes (20 cmH
2O) and higher MAP (10 cmH
2O vs. 8 cmH
2O). The survey published by Mukerji et al. [
40] do not specify the type of ventilators used for nHFOV. Therefore, comparing the parameters used in the surveys would be difficult. No difference was observed between the units as regards the number of NICU beds and admissions during the year prior to the survey (
Table 4). However, bigger units tend to use dedicated ventilators more frequently to provide nHFOV.
Most studies published in the literature report that nHFOV is a safe NIV mode [
10,
62], with beneficial results and no increase in adverse effects [
13,
19,
51,
55,
63]. Analysis of the part of our survey evaluating the secondary effects of nHFOV showed that leaks at the interface level (90.9%), thick secretions (81.8%), and secondary obstruction of the upper airway (63.9%) were the most common adverse effects noted by clinicians (
Table 3). This is in contrast to the results reported by Fischer et al. [
39] that showed that abdominal distension was the most common side effect observed (37% compared to 45.5% in our survey), followed by secretions obstructing the upper airways and thick secretion but with lower rates than our survey (27% and 23%, respectively). The increased leak rate at the interface level in our survey may be explained by the type of interface used – face/nasal masks in our survey – compared to prongs used by units reported in the Fischer et al. study [
39]. Increased secretions and secondary airway obstruction are often reported in the literature as a side effect of nHFOV [
24,
39] and are attributed to insufficient or inadequate gas conditioning as some of the humidifiers are not reaching the expected temperature and humidity [
64,
65,
66]. A combination of low frequencies, high amplitudes, and increased inspiratory to expiratory time significantly reduce the temperature and absolute humidity of the gases, increasing the risk for dryness of the upper airways [
64]. Agitation was noted far more often than in the Fischer et al. study [
39] (38.1% vs. 3%); this may be due to the patient’s discomfort with the interface or ineffective nursing strategies. Intolerance to feedings was reported by 3 of the units using nHFOV; others did not mention this side effect, and one comparative study mentioned decreased feeding tolerance with NIPPV compared to nHFOV [
3]. One study suggested that nHFOV, similar to NCPAP and NIPPIV, inhibits gastro-esophageal reflux in newborn lambs, mentioning that abdominal distension is the main trigger for inferior esophageal sphincter relaxation and reflux occurrence [
67].
Interest in nHFOV use among Romanian neonatologists is increasing. Lack of equipment was reported by 5 of the 10 units not using this nHFOV as the main reason for not using this NIV respiratory support, and 6 units reported insufficient nHFOV experience or training (
Table 4). Insufficient information or evidence on indications, settings, and outcomes were also reported in 30-40% of the cases. Although information and evidence on the beneficial effects and advantages of nHFOV are continuously increasing, experts are reporting that we still need more clear clinical indications for nHFOV (gestational age or birth weight criteria, types of respiratory conditions, severity of respiratory failure, settings for different indications) [
10,
21,
46]. Further studies may help establish a hierarchy of NIV support, with a more precise position of nHFOV among other NIV modes. There is also an urgent need for clear criteria to define nHFOV failure. As regards the information on the outcomes of the infants supported using nHFOV, up to now, there are few studies suggesting that similar to HFOV, there is no adverse effect on cerebral hemodynamics [
68] and no adverse effects compared to NCPAP and NIPPV after extubation [
69]. Indeed, we need more studies in this respect.
Our study has limitations that must be acknowledged. The number of units participating in the questionnaire is low, but over 90% of the units involved in the care of high-risk neonates in Romania responded; thus, we consider the results to be representative of nHFOV use, a recently introduced respiratory support mode in the country. There are aspects of nHFOV usage in practice not covered by the questionnaire, such as the inspiratory to expiratory ratio. The survey was designed for rapid completion. Thus, some questions related to parameter settings had multiple-choice answers, not allowing open answers, for example, other ways to choose the starting MAP on nHFOV or multiple choices for parameter settings with different indications of nHFOV. The timing of the survey around the training workshop on nHFOV could have been a source of bias. However, the survey was addressed to the leaders of the level III neonatal units who did not participate in the workshop. The statistical power of the comparative statistics between NICUs using nHFOV with dedicated versus hybrid ventilators must be interpreted with caution. Our survey did not evaluate the success rate of nHFOV. Still, the survey demonstrates an increased awareness and knowledge of nHFOV and an interest in extending its use in clinical practice. Also, the survey showed compliance with recent recommendations of the European guidelines for RDS management in preterm infants.